These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19052231)

  • 1. Characterizing heterogeneous cellular responses to perturbations.
    Slack MD; Martinez ED; Wu LF; Altschuler SJ
    Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19306-11. PubMed ID: 19052231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities.
    Singh DK; Ku CJ; Wichaidit C; Steininger RJ; Wu LF; Altschuler SJ
    Mol Syst Biol; 2010 May; 6():369. PubMed ID: 20461076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro investigations of new therapeutic agents on bladder tumor cell lines.
    Kugler A; Haschemi R; Zöller G; Gross AJ; Kallerhoff M; Ringert RH
    Urol Res; 1997; 25(4):247-50. PubMed ID: 9286032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumor heterogeneity alters most effective drugs in designed combinations.
    Zhao B; Hemann MT; Lauffenburger DA
    Proc Natl Acad Sci U S A; 2014 Jul; 111(29):10773-8. PubMed ID: 25002493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer.
    Lyons JM; Anthony CT; Thomson JL; Woltering EA
    Ann Surg Oncol; 2008 Dec; 15(12):3407-14. PubMed ID: 18795370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells.
    Friesen C; Herr I; Krammer PH; Debatin KM
    Nat Med; 1996 May; 2(5):574-7. PubMed ID: 8616718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel.
    Sobue S; Mizutani N; Aoyama Y; Kawamoto Y; Suzuki M; Nozawa Y; Ichihara M; Murate T
    Biochem Biophys Res Commun; 2016 Oct; 479(4):808-813. PubMed ID: 27687545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
    El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
    Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming.
    Romero OA; Verdura S; Torres-Diz M; Gomez A; Moran S; Condom E; Esteller M; Villanueva A; Sanchez-Cespedes M
    Oncogene; 2017 Mar; 36(9):1287-1296. PubMed ID: 27593925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trait variability of cancer cells quantified by high-content automated microscopy of single cells.
    Quaranta V; Tyson DR; Garbett SP; Weidow B; Harris MP; Georgescu W
    Methods Enzymol; 2009; 467():23-57. PubMed ID: 19897088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
    Viale M; Pastrone I; Pellecchia C; Vannozzi MO; Cafaggi S; Esposito M
    Anticancer Drugs; 1998 Jun; 9(5):457-63. PubMed ID: 9660544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diversity of the Senescence Phenotype of Cancer Cells Treated with Chemotherapeutic Agents.
    Bojko A; Czarnecka-Herok J; Charzynska A; Dabrowski M; Sikora E
    Cells; 2019 Nov; 8(12):. PubMed ID: 31771226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anticancer drugs and pharmacologic actions].
    Ogawa M
    Nihon Rinsho; 1997 May; 55(5):1017-23. PubMed ID: 9155146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel.
    Miglietta A; Cavalli R; Bocca C; Gabriel L; Gasco MR
    Int J Pharm; 2000 Dec; 210(1-2):61-7. PubMed ID: 11163988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of drug sensitivity by ribosomal protein S3a.
    Hu ZB; Minden MD; McCulloch EA; Stahl J
    Blood; 2000 Feb; 95(3):1047-55. PubMed ID: 10648421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
    Toffoli G; Corona G; Gigante M; Boiocchi M
    Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
    Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose of dexamethasone upregulates TCR/CD3-induced calcium response independent of TCR zeta chain expression in human T lymphocytes.
    Nambiar MP; Enyedy EJ; Fisher CU; Warke VG; Tsokos GC
    J Cell Biochem; 2001 Aug 21-Sep 5; 83(3):401-13. PubMed ID: 11596109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of camptothecin-sensitive chinese hamster cell mutants: phenotypic heterogeneity within the ataxia telangiectasia-like XRCC8 (irs2) complementation group.
    Johnson MA; Bryant PE; Jones NJ
    Mutagenesis; 2000 Jul; 15(4):367-74. PubMed ID: 10887218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line.
    Hochhauser D; Schnieders B; Ercikan-Abali E; Gorlick R; Muise-Helmericks R; Li WW; Fan J; Banerjee D; Bertino JR
    J Natl Cancer Inst; 1996 Sep; 88(18):1269-75. PubMed ID: 8797766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.